EP2794009 - BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 06.07.2018 Database last updated on 03.09.2024 | |
Former | The patent has been granted Status updated on 28.07.2017 | ||
Former | Grant of patent is intended Status updated on 20.03.2017 | ||
Former | Examination is in progress Status updated on 07.02.2017 | Most recent event Tooltip | 17.07.2020 | Lapse of the patent in a contracting state New state(s): AL | published on 19.08.2020 [2020/34] | Applicant(s) | For all designated states Kancera AB Karolinska Institutet Science Park Banvaktsvägen 22 17148 Solna / SE | [2014/44] | Inventor(s) | 01 /
MARTINSSON, Jessica Turebergs allé 13 S-191 64 Sollentuna / SE | 02 /
FÄRNEGÅRDH, Katarina Borstvetevägen 6 S-178 35 Ekerö / SE | 03 /
JÖNSSON, Mattias Forngravsvägen 4A S-741 42 Knivsta / SE | 04 /
RINGOM, Rune Murargatan 20a S-754 37 Uppsala / SE | [2014/48] |
Former [2014/44] | 01 /
MARTINSSON, Jessica Hästhagsvägen 23C S-191 63 Sollentuna / SE | ||
02 /
FÄRNEGÅRDH, Katarina Borstvetevägen 6 S-178 35 Ekerö / SE | |||
03 /
JÖNSSON, Mattias Forngravsvägen 4A S-741 42 Knivsta / SE | |||
04 /
RINGOM, Rune Murargatan 20a S-754 37 Uppsala / SE | Representative(s) | Brann AB P.O. Box 3690 Sveavägen 63 103 59 Stockholm / SE | [N/P] |
Former [2017/35] | Brann AB P.O. Box 3690 Drottninggatan 27 103 59 Stockholm / SE | ||
Former [2014/44] | Brann AB P.O. Box 12246 102 26 Stockholm / SE | Application number, filing date | 12806515.8 | 21.12.2012 | [2017/35] | WO2012EP76836 | Priority number, date | US201161579360P | 22.12.2011 Original published format: US 201161579360 P | EP20110195456 | 22.12.2011 Original published format: EP 11195456 | EP20110195962 | 28.12.2011 Original published format: EP 11195962 | [2014/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2013093095 | Date: | 27.06.2013 | Language: | EN | [2013/26] | Type: | A1 Application with search report | No.: | EP2794009 | Date: | 29.10.2014 | Language: | EN | The application published by WIPO in one of the EPO official languages on 27.06.2013 takes the place of the publication of the European patent application. | [2014/44] | Type: | B1 Patent specification | No.: | EP2794009 | Date: | 30.08.2017 | Language: | EN | [2017/35] | Search report(s) | International search report - published on: | EP | 27.06.2013 | Classification | IPC: | A61P35/00, A61P29/00, A61K31/381, A61K31/41, A61K31/18, A61K31/343, A61K31/427, A61K31/4436, A61K31/506, C07C311/13, C07C311/21, C07C311/27, C07C311/29, C07C311/39, C07C311/46 | [2014/44] | CPC: |
C07D409/14 (EP,US);
A61P1/00 (EP);
A61P29/00 (EP);
A61P35/00 (EP);
A61P43/00 (EP);
C07C311/21 (US);
C07D213/34 (EP,US);
C07D213/71 (EP,US);
C07D213/74 (EP,US);
C07D215/12 (EP,US);
C07D231/38 (EP,US);
C07D261/14 (EP,US);
C07D277/26 (EP,US);
C07D285/15 (EP,US);
C07D295/088 (EP,US);
C07D295/096 (EP,US);
C07D295/192 (EP,US);
C07D307/64 (EP,US);
C07D307/79 (EP,US);
C07D307/82 (EP,US);
C07D333/22 (EP,US);
C07D333/34 (EP,US);
C07D333/62 (EP,US);
C07D405/04 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/44] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | BISARYLSULFONAMIDE FÜR DIE BEHANDLUNG EINER ENTZÜNDUNG UND KREBS | [2016/35] | English: | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | [2014/44] | French: | BISARYLE-SULFONAMIDES UTILES POUR LE TRAITEMENT DES INFLAMMATIONS ET DU CANCER | [2016/35] |
Former [2014/44] | FÜR DIE BEHANDLUNG VON ENTZÜNDUNGEN UND KREBS NÜTZLICHE BISARYLSULFONAMIDE | ||
Former [2014/44] | BISARYLSULFONAMIDES UTILES DANS LE TRAITEMENT D'INFLAMMATIONS ET DE CANCER | Entry into regional phase | 08.07.2014 | National basic fee paid | 08.07.2014 | Designation fee(s) paid | 08.07.2014 | Examination fee paid | Examination procedure | 08.07.2014 | Examination requested [2014/44] | 23.01.2015 | Amendment by applicant (claims and/or description) | 28.10.2015 | Despatch of a communication from the examining division (Time limit: M04) | 01.02.2016 | Reply to a communication from the examining division | 25.10.2016 | Communication of intention to grant the patent | 06.02.2017 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 21.03.2017 | Communication of intention to grant the patent | 21.07.2017 | Fee for grant paid | 21.07.2017 | Fee for publishing/printing paid | 21.07.2017 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 28.10.2015 | Opposition(s) | 31.05.2018 | No opposition filed within time limit [2018/32] | Fees paid | Renewal fee | 30.12.2014 | Renewal fee patent year 03 | 14.12.2015 | Renewal fee patent year 04 | 15.12.2016 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 21.12.2012 | AL | 30.08.2017 | AT | 30.08.2017 | CY | 30.08.2017 | CZ | 30.08.2017 | DK | 30.08.2017 | EE | 30.08.2017 | HR | 30.08.2017 | LT | 30.08.2017 | LV | 30.08.2017 | MK | 30.08.2017 | PL | 30.08.2017 | PT | 30.08.2017 | RO | 30.08.2017 | RS | 30.08.2017 | SI | 30.08.2017 | SK | 30.08.2017 | SM | 30.08.2017 | TR | 30.08.2017 | BG | 30.11.2017 | NO | 30.11.2017 | GR | 01.12.2017 | IS | 30.12.2017 | [2020/34] |
Former [2020/28] | HU | 21.12.2012 | |
AT | 30.08.2017 | ||
CY | 30.08.2017 | ||
CZ | 30.08.2017 | ||
DK | 30.08.2017 | ||
EE | 30.08.2017 | ||
HR | 30.08.2017 | ||
LT | 30.08.2017 | ||
LV | 30.08.2017 | ||
MK | 30.08.2017 | ||
PL | 30.08.2017 | ||
PT | 30.08.2017 | ||
RO | 30.08.2017 | ||
RS | 30.08.2017 | ||
SI | 30.08.2017 | ||
SK | 30.08.2017 | ||
SM | 30.08.2017 | ||
TR | 30.08.2017 | ||
BG | 30.11.2017 | ||
NO | 30.11.2017 | ||
GR | 01.12.2017 | ||
IS | 30.12.2017 | ||
Former [2020/16] | HU | 21.12.2012 | |
AT | 30.08.2017 | ||
CY | 30.08.2017 | ||
CZ | 30.08.2017 | ||
DK | 30.08.2017 | ||
EE | 30.08.2017 | ||
HR | 30.08.2017 | ||
LT | 30.08.2017 | ||
LV | 30.08.2017 | ||
MK | 30.08.2017 | ||
PL | 30.08.2017 | ||
RO | 30.08.2017 | ||
RS | 30.08.2017 | ||
SI | 30.08.2017 | ||
SK | 30.08.2017 | ||
SM | 30.08.2017 | ||
TR | 30.08.2017 | ||
BG | 30.11.2017 | ||
NO | 30.11.2017 | ||
GR | 01.12.2017 | ||
IS | 30.12.2017 | ||
Former [2019/51] | HU | 21.12.2012 | |
AT | 30.08.2017 | ||
CY | 30.08.2017 | ||
CZ | 30.08.2017 | ||
DK | 30.08.2017 | ||
EE | 30.08.2017 | ||
HR | 30.08.2017 | ||
LT | 30.08.2017 | ||
LV | 30.08.2017 | ||
MK | 30.08.2017 | ||
PL | 30.08.2017 | ||
RO | 30.08.2017 | ||
RS | 30.08.2017 | ||
SI | 30.08.2017 | ||
SK | 30.08.2017 | ||
SM | 30.08.2017 | ||
BG | 30.11.2017 | ||
NO | 30.11.2017 | ||
GR | 01.12.2017 | ||
IS | 30.12.2017 | ||
Former [2019/47] | HU | 21.12.2012 | |
AT | 30.08.2017 | ||
CY | 30.08.2017 | ||
CZ | 30.08.2017 | ||
DK | 30.08.2017 | ||
EE | 30.08.2017 | ||
HR | 30.08.2017 | ||
LT | 30.08.2017 | ||
LV | 30.08.2017 | ||
PL | 30.08.2017 | ||
RO | 30.08.2017 | ||
RS | 30.08.2017 | ||
SI | 30.08.2017 | ||
SK | 30.08.2017 | ||
SM | 30.08.2017 | ||
BG | 30.11.2017 | ||
NO | 30.11.2017 | ||
GR | 01.12.2017 | ||
IS | 30.12.2017 | ||
Former [2019/31] | HU | 21.12.2012 | |
AT | 30.08.2017 | ||
CZ | 30.08.2017 | ||
DK | 30.08.2017 | ||
EE | 30.08.2017 | ||
HR | 30.08.2017 | ||
LT | 30.08.2017 | ||
LV | 30.08.2017 | ||
PL | 30.08.2017 | ||
RO | 30.08.2017 | ||
RS | 30.08.2017 | ||
SI | 30.08.2017 | ||
SK | 30.08.2017 | ||
SM | 30.08.2017 | ||
BG | 30.11.2017 | ||
NO | 30.11.2017 | ||
GR | 01.12.2017 | ||
IS | 30.12.2017 | ||
Former [2018/39] | AT | 30.08.2017 | |
CZ | 30.08.2017 | ||
DK | 30.08.2017 | ||
EE | 30.08.2017 | ||
HR | 30.08.2017 | ||
LT | 30.08.2017 | ||
LV | 30.08.2017 | ||
PL | 30.08.2017 | ||
RO | 30.08.2017 | ||
RS | 30.08.2017 | ||
SI | 30.08.2017 | ||
SK | 30.08.2017 | ||
SM | 30.08.2017 | ||
BG | 30.11.2017 | ||
NO | 30.11.2017 | ||
GR | 01.12.2017 | ||
IS | 30.12.2017 | ||
Former [2018/24] | AT | 30.08.2017 | |
CZ | 30.08.2017 | ||
DK | 30.08.2017 | ||
EE | 30.08.2017 | ||
HR | 30.08.2017 | ||
LT | 30.08.2017 | ||
LV | 30.08.2017 | ||
PL | 30.08.2017 | ||
RO | 30.08.2017 | ||
RS | 30.08.2017 | ||
SK | 30.08.2017 | ||
SM | 30.08.2017 | ||
BG | 30.11.2017 | ||
NO | 30.11.2017 | ||
GR | 01.12.2017 | ||
IS | 30.12.2017 | ||
Former [2018/23] | AT | 30.08.2017 | |
CZ | 30.08.2017 | ||
DK | 30.08.2017 | ||
EE | 30.08.2017 | ||
HR | 30.08.2017 | ||
LT | 30.08.2017 | ||
LV | 30.08.2017 | ||
PL | 30.08.2017 | ||
RO | 30.08.2017 | ||
RS | 30.08.2017 | ||
SK | 30.08.2017 | ||
BG | 30.11.2017 | ||
NO | 30.11.2017 | ||
GR | 01.12.2017 | ||
IS | 30.12.2017 | ||
Former [2018/21] | AT | 30.08.2017 | |
CZ | 30.08.2017 | ||
DK | 30.08.2017 | ||
HR | 30.08.2017 | ||
LT | 30.08.2017 | ||
LV | 30.08.2017 | ||
RS | 30.08.2017 | ||
BG | 30.11.2017 | ||
NO | 30.11.2017 | ||
GR | 01.12.2017 | ||
IS | 30.12.2017 | ||
Former [2018/12] | AT | 30.08.2017 | |
HR | 30.08.2017 | ||
LT | 30.08.2017 | ||
LV | 30.08.2017 | ||
RS | 30.08.2017 | ||
BG | 30.11.2017 | ||
NO | 30.11.2017 | ||
GR | 01.12.2017 | ||
IS | 30.12.2017 | ||
Former [2018/11] | AT | 30.08.2017 | |
HR | 30.08.2017 | ||
LT | 30.08.2017 | ||
RS | 30.08.2017 | ||
BG | 30.11.2017 | ||
NO | 30.11.2017 | ||
GR | 01.12.2017 | ||
IS | 30.12.2017 | ||
Former [2018/10] | AT | 30.08.2017 | |
HR | 30.08.2017 | ||
LT | 30.08.2017 | ||
RS | 30.08.2017 | ||
NO | 30.11.2017 | ||
Former [2018/07] | LT | 30.08.2017 | |
NO | 30.11.2017 | Cited in | International search | [A]EP0269859 (OTSUKA PHARMA CO LTD [JP]) [A] 1-19 * abstract * * example 112 *; | [A]US2004167128 (COMESS KENNETH M [US], et al) [A] 1-19 * abstract * * page 22 - page 120; examples 1-618 * * claims 1-21 *; | [A]WO2005060963 (PFIZER [US], et al) [A] 1-19 * abstract * * page 55 - page 96; table 1 * * claims 1-19 *; | [A]WO2008156783 (UNIV LOUISVILLE RES FOUND [US], et al) [A] 1-19 * abstract * * claims 1-77 *; | [A]WO2010076034 (EUROPEAN MOLECULAR BIOLOGY LAB EMBL [DE], et al) [A] 1-19 * abstract * * page 47 - page 49; table 2; compounds 1-29 * * page 51 - page 57; table 3; compounds 30-280 * * claims 1-19 *; | [A]CN101817767 (SHANGHAI INST BIOL SCIENCES, et al) [A] 1-19 * abstract * * paragraphs [0045] - [0047] * * claims *; | [A]US2010267815 (TELANG SUCHETA [US], et al) [A] 1-19 * abstract * * claims 1-28 *; | [A]WO2011103557 (ADVANCED CANCER THERAPEUTICS LLC [US], et al) [A] 1-19 * abstract * * claims 1-12 *; | [XP]WO2011161201 (KANCERA AB [SE], et al) [XP] 16* the whole document *; | [A] - CROCHET R B ET AL H, "Investigating combinatorial approaches in virtual screening on human inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3): A case study for small molecule kinases", ANALYTICAL BIOCHEMISTRY 20111101 ACADEMIC PRESS INC. USA LNKD- DOI:10.1016/J.AB.2011.06.035, (20111101), vol. 418, no. 1, ISSN 0003-2697, pages 143 - 148, XP002672410 [A] 1-19 * abstract * * page 146; figure 3 * DOI: http://dx.doi.org/10.1016/J.AB.2011.06.035 | [A] - W. O. GODTFREDSEN ET AL, "Antitubercular Compounds Related to p-Aminosalicylic Acid.", ACTA CHEMICA SCANDINAVICA, (19530101), vol. 7, doi:10.3891/acta.chem.scand.07-0781, ISSN 0904-213X, pages 781 - 789, XP055050836 [A] 1-19 * abstract * * page 785; table 7; compound first * DOI: http://dx.doi.org/10.3891/acta.chem.scand.07-0781 | [A] - DRAIN D J ET AL, "4-Aminosalicylic Acid and its Derivatives", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL SOCIETY, LETCHWORTH; GB, (19490101), doi:10.1039/JR9490001498, ISSN 0368-1769, pages 1498 - 1503, XP002084241 [A] 1-19 * abstract * * methyl 4-acetylsulphanilamidosalicylate; page 1502 * DOI: http://dx.doi.org/10.1039/jr9490001498 | [A] - TAMAZAWA K ET AL, "Synthesis of [carbonyl-<14>C]- and (methoxy-d3)-labeled N-[(2RS, 3RS)-1-benzyl-2-methyl-3-pyrrolidinyl]-5-chloro-2-methoxy-4-(methylam ino)b enzamide (YM-09151-2) a new potent neuroleptic agent", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS 1984 GB, (1984), vol. 21, no. 5, ISSN 0362-4803, pages 441 - 453, XP002672411 [A] 1-19 * abstract * * page 443; compounds 3a,c * DOI: http://dx.doi.org/10.1002/jlcr.2580210507 | [A] - K. BENEDIKT AND H. EIBL, "Über einige Derivate der p-Aminosalicylsäure und ihre tuberkulostatische Wirksamkeit", MONATSHEFTE FÜR CHEMIE / CHEMICAL MONTHLY, (1949), vol. 81, no. 3, doi:10.1007/BF00903044, pages 419 - 423, XP002672412 [A] 1-19 * 4-Acetylsulfanylamido-salicylsäureäthylester; page 421; table 1 * DOI: http://dx.doi.org/10.1007/BF00903044 | [A] - ANGULO, J.; MUNICIO, A. M., "Potential antitubercular compounds. II. Synthesis of pyridine-4-sulfonamides", ANALES DE LA REAL SOCIEDAD ESPANOLA DE FISICA Y QUIMICA, SERIE B: QUIMICA, (19590101), vol. 55B, ISSN 0034-088X, pages 527 - 532, XP008159576 [A] 1-19 * abstract * * page 530; table -; compounds p-aminosalicilato etilo * | [A] - WENDT B ET AL, "Toluidinesulfonamide hypoxia-induced factor 1 inhibitors: Alleviating drug-drug interactions through use of pubchem data and comparative molecular field analysis guided synthesis", JOURNAL OF MEDICINAL CHEMISTRY 20110609 AMERICAN CHEMICAL SOCIETY USA LNKD- DOI:10.1021/JM200272H, (20110609), vol. 54, no. 11, ISSN 0022-2623, pages 3982 - 3986, XP002672413 [A] 1-19 * abstract * * page 3983; table 1; compounds 1-7 * DOI: http://dx.doi.org/10.1021/JM200272H | by applicant | WO0076984 | US6465467 | WO2008156783 | US2010267815 | WO2011103557 | US2012302631 | - WARBURG, SCIENCE, (1956), vol. 123, pages 309 - 314 | - VANDER HEIDEN ET AL., SCIENCE, (2009), vol. 324, page 1029 | - BROWN, CANCER RES., (1999), vol. 59, pages 5863 - 5870 | - WALENTA; MUELLER-KLIESER, SEMIN. RADIAT. ONCOL., (2004), vol. 14, pages 267 - 274 | - WALENTA ET AL., CURR.MED. CHEM., (2004), vol. 11, pages 2195 - 2204 | - PAN; MAK, SCI. STKE, (2007), vol. 381, page EL4 | - BACHE ET AL., CURR. MED. CHEM., (2008), vol. 15, pages 322 - 338 | - LIU ET AL., BIOCHEMISTRY, (2001), vol. 40, no. 5, pages 542 - 5547 | - LIU ET AL., BIOCHEM. PHARMACOL., (2002), vol. 64, pages 1745 - 1751 | - XU ET AL., CANCER RES., (2005), vol. 65, pages 613 - 621 | - RAMANATHAN ET AL., PROC. NATL. ACAD. SCI. USA, (2005), vol. 102, pages 5992 - 5997 | - CHESNEY ET AL., PROC.NATL. ACAD. SCI. USA, (1999), vol. 96, pages 3047 - 3052 | - TELANG ET AL., ONCOGENE, (2006), vol. 25, pages 7225 - 7234 | - ANDO ET AL., J NIPPON MED SCH, (2010), vol. 77, no. 2, pages 97 - 105 | - DEL REY ET AL., ARTHRITIS & RHEUMATISM, (2010), vol. 62, pages 3584 - 3594 | - MINCHENKO ET AL., FEBS LETT., (2004), vol. 576, pages 14 - 20 | - MINCHENKO ET AL., BIOCHEMIE, (2005), vol. 87, pages 1005 - 1010 | - BO- BARYKINA ET AL., ACTA BIOCHEMICA POLONICA, (2006), vol. 3, pages 789 - 799 | - ROS ET AL., CANCER DISCOV., (2012), vol. 2, no. 4, pages 328 - 43 | - SAKAKIBARA ET AL., J. BIO CHEM, (1984), vol. 259, pages 14023 - 14028 | - HIRATA ET AL., BIOSCI. BIOTECHNOL. BIOCHEM., (2000), vol. 64, pages 2047 - 2052 | - KIM ET AL., J. MOL. BIOL., (2007), vol. 370, pages 14 - 26 | - CHROCHET ET AL., ANAL. BIOCHEM., (2011), vol. 418, pages 143 - 148 | - SEO ET AL., PLOSONE, (2011), vol. 9, page E24179 | - CLEM ET AL., MOL. CANCER THER., (2008), vol. 7, pages 110 - 120 | - "Biotransformation of Drugs", GOODMAN; GILMAN'S, The Pharmacological basis of Therapeutics, 8th ed.,, MCGRAW-HILL, (1992), pages 13 - 15 | - PLÉ ET AL., J. HETEROCYCLIC CHEM., (1988), vol. 25, pages 1271 - 1272 | - XIE ET AL., TETRAHEDRON LETT., (2004), vol. 45, pages 6235 - 6237 | - GRAHAM ET AL., J. MED. CHEM., (1990), vol. 33, pages 749 - 754 | - PAQUETTE, Encyclopedia of Reagents for Organic Synthesis | - JIANG ET AL., TETRAHEDRON LETT., (2006), vol. 47, pages 197 - 200 | - HARRIS ET AL., ORG. LETT, (2001), vol. 3, no. 21, pages 3417 - 3419 | - PIE ET AL., J. HETEROCYCLIC CHEM., (1988), vol. 25, pages 1271 - 1272 | - PILKIS ET AL., ANNU. REV. BIOCHEM., (1995), vol. 64, pages 799 - 835 | - OKAR ET AL., TRENDS BIOCHEM. SCI., (2001), vol. 26, pages 30 - 5 | - RIDER ET AL., BIOCHEM J., (2007), vol. 381, pages 561 - 579 | - VAN SCHAFTINGEN ET AL., EUR. J. BIOCHEM., (1982), vol. 129, pages 191 - 5 | - VAN SCHAFTINGEN, Methods of Enzymatic Analysis, 3rd edn.,, VERLAG CHEMIE, (1984), vol. 6, pages 335 - 341 | - BRUNI ET AL., ANAL. BIOCHEM., (1989), vol. 178, pages 324 - 6 |